IntegraGen
Company

Last deal

$2.4M

Amount

Post-IPO Equity

Stage

13.07.2012

Date

4

all rounds

$12.2M

Total amount

General

About Company
IntegraGen develops molecular markers for CNS and metabolic diseases, leveraging its IP, research expertise, and sample libraries.

Industry

Sector :

Subsector :

founded date

01.01.2000

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The French biotech company offers genomic and bioinformatic services, including clinical research, genetic research, bioinformatics, and bioanalysis, as well as research tools and solutions to microbiologic researchers. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. It generated €9 million of revenue in 2020 and is part of the OncoDNA group, which provides biomarker testing and clinical interpretation tools to guide cancer treatment and drug development.